News

Tuesday, 13. November 2012

Insmed Announces CLEAR-108 Phase 3 Clinical Study of ARIKACE

Insmed Announces CLEAR-108 Phase 3 Clinical Study of ARIKACE in Cystic Fibrosis Patients with Pseudomonas Lung Infections Has Completed Target Enrollment

MONMOUTH JUNCTION, N.J., Nov. 13, 2012 /PRNewswire/ -- Insmed Incorporated Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today announced that the Company's Clinical Evaluation of ARIKACE (CLEAR-108) phase 3 European and Canadian registrational study of ARIKACE (liposomal amikacin for inhalation) for Cystic Fibrosis (CF) patients with Pseudomonas aeruginosa (Pa) lung infections has now enrolled over 300 patients.

Entire press release available below.